OIS at AAO 2015

Iconic Therapeutics

Nov 12, 2015 12:05pm ‐ Nov 12, 2015 12:13pm


Description

Iconic Therapeutics is a clinical stage biopharmaceutical company developing new therapeutics for retinal diseases and cancer. Iconic’s lead product candidate, ICON-1, a novel fusion protein that targets Tissue Factor, is in Phase 2 development for wet AMD. Iconic is backed by MPM Capital, H.I.G. Bioventures and Lundbeckfond Ventures.

Speaker(s):

You must be logged in and own this session in order to post comments.

Print Certificate
Review Answers
Print Transcript
Completed on: token-completed_on
Review Answers
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
* - Indicates answer is required.
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content